OncoBriefs - Oncology Research News

April 23, 2026

Two Doors, One Tumor

Two Doors, One Tumor

Door A: You're a dendritic cell. Someone hands you a package - an mRNA vaccine wrapped in a standard lipid nanoparticle, the same delivery tech that saved civilization during COVID. You open the package, read the mRNA, and... mostly shrug. The tumor lives. Zero percent of the mice survive...

April 23, 2026

What If Your Cancer Could Just Hold Its Breath?

What If Your Cancer Could Just Hold Its Breath?

What if the tumor inside you could simply pretend to be dead while chemotherapy raged through your body, then yawn, stretch, and start growing again the moment the drugs cleared out? Not because it mutated into some indestructible supervillain, but because it pulled the biological equivalent of...

April 22, 2026

Breast Cancer's Secret Road Trip to Your Heart

Breast Cancer's Secret Road Trip to Your Heart

The fibroblast never planned on a career change. For years, it sat quietly in atrial tissue, minding its own business, patching up minor wear and tear like a dependable road crew filling potholes. But somewhere along the route between a breast tumor and the heart's upper chambers, a signal arrived...

April 22, 2026

Repurposed.

Repurposed.

That single word carries more weight in oncology than most people realize. For over half a century, I have watched the field chase shiny new molecules - and occasionally stumble upon something remarkable hiding in plain sight inside the medicine cabinet. Ponatinib, a drug that has spent the better...

April 22, 2026

Retreatment with RET Inhibitors: Going Back to the Well

Retreatment with RET Inhibitors: Going Back to the Well

Going once, going twice - sold to the oncologist recycling the same drug class! In the high-stakes auction of cancer treatment options, what happens when you've already played your best card and need to bid again with something suspiciously similar? That's the question a team of researchers just...

April 22, 2026

The Verdict Is In: A Multimodal Strike Against Glioblastoma

The Verdict Is In: A Multimodal Strike Against Glioblastoma

Ladies and gentlemen of the jury, the prosecution would like to present Exhibit A: glioblastoma multiforme (GBM), the most aggressive brain tumor known to medicine, a repeat offender with a rap sheet longer than a Law & Order marathon. For decades, the defense - our immune system - has been...

April 21, 2026

Meanwhile, in a Breast Cancer Cell's Nucleus...

Meanwhile, in a Breast Cancer Cell's Nucleus...

Meanwhile, in a breast cancer cell's nucleus, thousands of long non-coding RNAs are lounging around like freeloaders at a party nobody remembers inviting them to. Scientists used to think these molecular squatters were just "junk" transcripts - the biological equivalent of that one drawer in your...

April 21, 2026

The Leaky Pipes of Leukemia

The Leaky Pipes of Leukemia

Think of your bone marrow as a building's plumbing system - a sprawling, intricate network of pipes carrying signals that tell blood cells when to grow, when to stop, and when to gracefully retire. Now imagine one of those pipes - let's call it FLT3 - develops a kink. Not the kind a plumber fixes...

April 21, 2026

VarNet-T - Tumor-Only Variant Calling

VarNet-T - Tumor-Only Variant Calling

Making a soufflé without a recipe is a bold move. Making one without ever having tasted a soufflé? That's basically what cancer genomics has been trying to do every time it analyzes a tumor sample without its matching "normal" DNA reference. You're staring at thousands of genetic changes, trying to...

April 20, 2026

Previously on "CAR T Cells vs. AML"...

Previously on "CAR T Cells vs. AML"...

When we last left our heroes, the plucky engineered immune cells known as CAR T cells had conquered lymphoma and myeloma with the swagger of a championship team on a winning streak. But AML - acute myeloid leukemia - remained the villain they couldn't quite crack. The tumor microenvironment was...

April 20, 2026

The Tobemstomig Blog Post

The Tobemstomig Blog Post

"But wait, there's more!" If your immune system's anti-cancer squad has been underperforming - if those T-cells are dragging themselves through the tumor microenvironment like contestants on season 47 of Survivor - then boy, does Roche have the infomercial product for you. Introducing tobemstomig:...

April 20, 2026

The Verdict on Second Chances: Can Chemoimmunotherapy Rescue Recurrent Head and Neck Cancer?

The Verdict on Second Chances: Can Chemoimmunotherapy Rescue Recurrent Head and Neck Cancer?

Members of the jury, the evidence is in. For years, the case against recurrent head and neck squamous cell carcinoma (HNSCC) has felt almost unwinnable. The prosecution - an army of surgeons, oncologists, and radiation therapists - threw everything they had at the tumor the first time around....

April 19, 2026

Mitochondrial Dynamics: The Cellular Power Play Against Cancer

Mitochondrial Dynamics: The Cellular Power Play Against Cancer

In Ant-Man and the Wasp, the heroes discover that the key to saving the day isn't some galaxy-sized weapon - it's mastering the quantum realm, a world so tiny it makes atoms look like beach balls. Turns out, cancer researchers have been on a remarkably similar quest. Deep inside your cells,...

April 19, 2026

Screening for Breast Cancer: When Finding More Isn't Always Winning

Screening for Breast Cancer: When Finding More Isn't Always Winning

A fly on the wall in the offices of JAMA this spring would have witnessed something remarkable: a polite but pointed academic cage match over one of the biggest questions in cancer medicine. On one side, three epidemiologists - Frerik Smit, Jay Kaufman, and Arnaud Chiolero - raising an eyebrow at...

April 19, 2026

Six Proteins Walk Into a Lab

Six Proteins Walk Into a Lab

The pathologist was halfway through her third coffee when the mass spectrometer spat out something that made her set the mug down. Buried in the proteomic data from 759 tumor samples, six proteins were practically screaming about which stage III colon cancer patients would relapse - and which ones...

April 19, 2026

The Tumor's Witness Protection Program Has Multiple Safe Houses

The Tumor's Witness Protection Program Has Multiple Safe Houses

Triple-negative breast cancer is the villain nobody roots for. It's aggressive, it's sneaky, and it refuses to carry the molecular handles - estrogen, progesterone, and HER2 receptors - that doctors normally grab onto when selecting treatments. About 30% of TNBC patients who receive neoadjuvant...

April 19, 2026

Two Drugs Walk Into a Leukemia Cell: CPX-351 vs. Venetoclax-HMA in the Battle for AML

Two Drugs Walk Into a Leukemia Cell: CPX-351 vs. Venetoclax-HMA in the Battle for AML

Deep inside the bone marrow, a covert operation has been running for decades. Acute myeloid leukemia - AML for short - is the double agent that slipped past your body's counterintelligence, forging fake IDs for rogue blood cells and smuggling them into circulation. For years, oncologists have been...

April 18, 2026

*Bzzzzzt.*

*Bzzzzzt.*

That's not the sound of a bug zapper on your porch. It's the sound of electric fields scrambling cancer cells in someone's pancreas - and the FDA just gave it a thumbs up.